Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s): ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

TSX:ATE - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by Duster340on Nov 14, 2023 1:35pm

252 Views

Post# 35734859

Just for fun

lets do some quick math. as of september/30 end of Q2 antibe has 27.9M
nuance likely to win arbitration 20M
aproximatley 2 years of interest (ball park figure @4%) = 1.632M

27.9M - 20M - 1.632M = 6.268M
cash burn in Q2 was 6.4M, ok so lets go conservative and price in a cash burn the rest of the way @5M flat per quarter.
end of Q3 6.4M - 5M = 1.4M cash left
end of Q4 -5M we run out of cash before the end of Q4, P2 starts in Q1 2024 results in Q3 2024
end of Q1 another-5M

https://www.bankofcanada.ca/rates/related/investment-calculator/

<< Previous

Bullboard Posts

Next >>

Odd Burger to add 40 locations in Florida